With the comment period ending today, the proposed CMS cuts to radiation oncology reimbursement rates might have a substantial impact on community treatment centers.
The comment period for the Medicare Physician Fee Schedule (MPFS) for the year 2016 ends today and physicians have not held back in expressing concerns and their opposition to some of the provisions within the MPFS. The main opposition comes from community oncology centers and freestanding cancer care facilities who would have the most impact of the proposed cuts. According to the proposal, there would be a 3% reduction in payments to the overall radiation oncology specialty, although the cuts would vary depending on the patient population and could even reach 10%.
Some of the proposed changes by CMS for radiation oncology include:
· The implementation of new treatment delivery codes which were delayed in the CY 2016 PFS Final Rule as well as CMS modifications to those codes
· CMS's proposal to increase the equipment utilization assumption for the linear accelerator from 50% to 70%
· Corresponding increases in other radiation oncology codes due to an increase in the indirect practice cost index.
Immediately following the proposed policy and payment changes, The American Society for Radiation Oncology (ASTRO) issued a press release expressing concern over the cuts. “The implementation of these three dramatic policy changes at once represents too much, too fast for community-based clinics to absorb and could have devastating effects, particularly for those centers in rural and underserved areas,” said ASTRO chair Bruce G. Haffty, MD, FASTRO, in the release.
In a related blog on The Hill, Christopher M. Rose, MD, chief technology officer at Vantage Oncology, Inc—a coalition of 296 freestanding cancer care facilities across 35 states—writes that the proposed changes could have devastating effects on care delivery and patient access, especially the more vulnerable populations. “If the proposed PFS changes were adopted, the payments for a course of care for prostate and breast cancer will be reduced by 25% and 19%, respectively. Furthermore, this same care will be reimbursed 36% less and 32% less, respectively, in the freestanding setting than care delivered in the hospital setting,” he writes.
The final rule is expected to be issued by November 1, 2015 and the ruling will be effective January 1, 2016.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More